Back to Screener

Estrella Immunopharma, Inc. Warrant (ESLAW)

Price$0.10

Favorite Metrics

Price vs S&P 500 (4W)66.07%

All Metrics

Price vs S&P 500 (YTD)95.12%
10-Day Avg Trading Volume0.00M
3-Month Avg Trading Volume0.01M
52-Week High$0.24
13-Week Price Return135.29%
3-Month Return Std Dev382.59%
Year-to-Date Return100.00%
5-Day Price Return-27.22%
Month-to-Date Return33.51%
Price vs S&P 500 (13W)134.16%
Beta0.91x
52-Week Low$0.03

Industry Peers — Biological Products(89)

SymbolP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
ESLAWEstrella Immunopharma, Inc. Warrant
$0.10
AMGNAmgen Inc
5.20x9.95%73.30%2.93%$350.16
GILDGilead Sciences Inc
5.71x2.40%78.83%133.64%$135.87
ARGXargenx SE American Depositary Shares
12.59x89.56%150.91%$834.45
BNTXBioNTech SE American Depositary Share
9.06x-11.81%84.21%$105.19
BIIBBiogen Inc. Common Stock
2.72x2.22%75.69%-18.77%$183.34
MRNAModerna, Inc. Common Stock
10.91x-39.93%70.32%$54.59
NBIXNeurocrine Biosciences Inc
4.64x21.45%98.18%2.31%$131.59
EXELExelixis Inc
4.89x6.85%96.39%31.10%$43.61
TECHBio-Techne Corp.
7.72x1.64%66.60%-20.58%$60.58
IBRXImmunityBio, Inc. Common Stock
74.42x668.31%99.34%$8.20

About

Estrella Immunopharma is a clinical-stage biopharmaceutical company developing ARTEMIS T-cell therapies targeting CD19 and CD22 for blood cancers, solid tumors, and autoimmune diseases. The company's engineered T-cell approach addresses current treatment limitations in oncology and immunology.